It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...
Hosted on MSN2mon
Beyfortus RSV treatment to launch in Korea next monthYun Ki-wook, a professor in SNUH's Department of Pediatric Infectious Diseases, discusses the domestic release of Beyfortus, an antibody treatment for respiratory syncytial virus, during a press ...
A study today in JAMA Network Open from the University of California, San Francisco (UCSF), shows a high uptake of respiratory syncytial virus (RSV) vaccine and the RSV-preventing monoclonal antibody ...
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...
SNY’s RSV vaccine, called Beyfortus, was a key driver for its previous quarter, and its Q4 could be a repeat since it’s typically seasonally strong for vaccines. The company also has a robust ...
Chief Executive Officer Paul Hudson is focused on boosting Sanofi’s drug development, hoping to produce more blockbusters like Beyfortus, which protects against the respiratory syncytial virus.
Sanofi could be "bit more" active with M&A in near future, CFO says Sanofi's R&D spending to see limited increase in 2025 Beyfortus sales double, Dupixent sales miss estimates Jan 30 - Sanofi ...
Beyfortus reached blockbuster status in its first full year of sales, contributing significantly to the company's growth. The company's vaccines business crossed the EUR8 billion milestone ...
Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with Beyfortus becoming a blockbuster in its first full year of sales. We exceeded our business EPS ...
Management expects Beyfortus penetration to grow further with geographic expansion. Gross margin and R&D expenses are also anticipated to increase slightly in 2025, supported by preparations for u ...
Sobi's acquired immunology drugs (Astra's Synagis and Beyfortus, Novimmune's Gamifant, Apellis' Aspaveli) and hematology drugs (Dova's platelet drug Doptelet, ADC's blood cancer drug Zynlonta ...
Higher sales of Dupixent and contributions from new products like Altuviiio and Beyfortus were partially offset by lower sales of flu vaccines and Aubagio due to generic competition. Dupixent’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results